Literature DB >> 33942712

Postlaunch evidence-generation studies for medical devices in Spain: the RedETS approach to integrate real-world evidence into decision making.

Pedro Serrano-Aguilar1,2,3,4, Iñaki Gutierrez-Ibarluzea2,5,6, Pilar Díaz2,7, Iñaki Imaz-Iglesia2,3,8, Jesús González-Enríquez2,3,8, José Luis Castro2,9, Mireia Espallargues2,3,10, Sandra García-Armesto2,11, Paloma Arriola-Bolado2,12, Amado Rivero-Santana2,3,4,13, Lilisbeth Perestelo-Pérez1,2,3,4, Himar González-Pacheco2,13, Yolanda Álvarez-Pérez2,13, María José Faraldo-Vallés2,14, Janet Puñal-Riobóo2,14, Yolanda Ramallo-Fariña2,3,4,13, Luis María Sánchez-Gómez2,3,8,15, José Asua-Batarrita2,16, Eva Reviriego-Rodrigo2,16,17, Anai Moreno-Rodríguez18, Celia Juárez-Rojo2, Marisa Vicente-Saiz7, Eugenia Orejas-Pérez7, Jutta Knabe-Guerra2, Isabel Prieto-Yerro2,19, Cristina González Del Yerro-Valdés2,19.   

Abstract

The Monitoring Studies (MS) program, the approach developed by RedETS to generate postlaunch real-world evidence (RWE), is intended to complement and enhance the conventional health technology assessment process to support health policy decision making in Spain, besides informing other interested stakeholders, including clinicians and patients. The MS program is focused on specific uncertainties about the real effect, safety, costs, and routine use of new and insufficiently assessed relevant medical devices carefully selected to ensure the value of the additional research needed, by means of structured, controlled, participative, and transparent procedures. However, despite a clear political commitment and economic support from national and regional health authorities, several difficulties were identified along the development and implementation of the first wave of MS, delaying its execution and final reporting. Resolution of these difficulties at the regional and national levels and a greater collaborative impulse in the European Union, given the availability of an appropriate methodological framework already provided by EUnetHTA, might provide a faster and more efficient comparative RWE of improved quality and reliability at the national and international levels.

Entities:  

Keywords:  Decision making; Europe; Postlaunch evidence-generation studies; Real-world evidence; Technology assessment

Year:  2021        PMID: 33942712     DOI: 10.1017/S0266462321000295

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  1 in total

1.  Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.

Authors:  Carlo Federici; Vivian Reckers-Droog; Oriana Ciani; Florian Dams; Bogdan Grigore; Zoltán Kaló; Sándor Kovács; Kosta Shatrov; Werner Brouwer; Michael Drummond
Journal:  Eur J Health Econ       Date:  2021-06-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.